Impact of Sulphonylureas on Neurodevelopmental Outcomes in KCNJ11-related Intermediate Developmental Delay, Epilepsy and Neonatal Diabetes (iDEND) Syndrome

Plain-language summary

This study examines the effect of sulfonylurea drugs on nervous system development in patients with KCNJ11-related intermediate developmental delay, epilepsy, and neonatal diabetes (iDEND syndrome). It enrolls patients aged 2 and older who carry the V59M mutation in the KCNJ11 gene and who successfully transitioned to oral sulfonylurea therapy. It is a trial without an assigned phase and is currently recruiting participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Recruiting

Sponsor

Royal Devon and Exeter NHS Foundation Trust

Intervention

Sulfonylurea

Start date

7/1/2016

Estimated completion

12/31/2025

Countries

United States, Italy, Norway, United Kingdom

Related genes

Locations

• Chicago, United States
• Rome, Italy
• Bergen, Norway
• Exeter, United Kingdom

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Current age ≥2 years
* Heterozygous for a V59M mutation in the KCNJ11 gene
* Successfully transferred to oral sulphonylurea therapy
* Willing to participate

Exclusion Criteria:

* Never able to transfer to oral sulphonylurea therapy
* Unwilling to participate